BiondVax Pharmaceuticals Ltd. | CIK:0001611747 | 3

  • Filed: 4/30/2018
  • Entity registrant name: BiondVax Pharmaceuticals Ltd. (CIK: 0001611747)
  • Generator: Ez-XBRL
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1611747/000121390018005179/0001213900-18-005179-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1611747/000121390018005179/bvxv-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001611747
  • Open this page in separate window: Click
  • ifrs-full:DisclosureOfFirstTimeAdoptionExplanatory

    NOTE 4:- DISCLOSURE OF NEW STANDARDS IN THE PERIOD PRIOR TO THEIR ADOPTION

     

    a. IFRS 9-Financial Instruments:

     

    In July 2014, the IASB issued the final and complete version of IFRS 9, “Financial Instruments” (“IFRS 9”), which replaces IAS 39, “Financial Instruments: Recognition and Measurement”. IFRS 9 mainly focuses on the classification and measurement of financial assets and it applies to all assets in the scope of IAS 39.

     

    IFRS 9 also includes a new model for measurement of impairment of financial assets.

     

    According to IFRS 9, the provisions of IAS 39 will continue to apply to derecognition and to financial liabilities for which the fair value option has not been elected.

     

    IFRS 9 is to be applied for annual periods beginning on January 1, 2018. Early adoption is permitted.

     

    The Company believes that the adoption of IFRS 9 is not expected to have a material impact on the financial statements.

     

    b. IFRS 16, “Leases”:

     

    In January 2016, the IASB issued IFRS 16, “Leases” (“the new Standard”). According to the new Standard, a lease is a contract, or part of a contract, that conveys the right to use an asset for a period of time in exchange for consideration.

     

    According to the new Standard:

     

    Lessees are required to recognize an asset and a corresponding liability in the statement of financial position in respect of all leases (except in certain cases) similar to the accounting treatment of finance leases according to the existing IAS 17, “Leases”.

     

    The new Standard is effective for annual periods beginning on or after January 1, 2019.

     

    For leases existing at the date of transition, the new Standard permits lessees to use either a full retrospective approach, or a modified retrospective approach, with certain transition relief whereby restatement of comparative data is not required.

     

    The Company is evaluating the possible effects of the new Standard. At this stage, the Company is unable to quantify the impact on the financial statements.